| 000 | 01617 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515195332.0 | ||
| 264 | 0 | _c20100304 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.01316-09 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAdam, Heather J | |
| 245 | 0 | 0 |
_aDetection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cFeb 2010 |
||
| 300 |
_a945-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCanada _xepidemiology |
| 650 | 0 | 4 |
_aCross Infection _xdrug therapy |
| 650 | 0 | 4 | _aDrug Resistance, Multiple, Bacterial |
| 650 | 0 | 4 |
_aMethicillin-Resistant Staphylococcus aureus _xdrug effects |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aStaphylococcal Infections _xdrug therapy |
| 650 | 0 | 4 |
_aVancomycin _xtherapeutic use |
| 650 | 0 | 4 |
_aVancomycin Resistance _xgenetics |
| 700 | 1 | _aLouie, Lisa | |
| 700 | 1 | _aWatt, Christine | |
| 700 | 1 | _aGravel, Denise | |
| 700 | 1 | _aBryce, Elizabeth | |
| 700 | 1 | _aLoeb, Mark | |
| 700 | 1 | _aMatlow, Anne | |
| 700 | 1 | _aMcGeer, Allison | |
| 700 | 1 | _aMulvey, Michael R | |
| 700 | 1 | _aSimor, Andrew E | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 54 _gno. 2 _gp. 945-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.01316-09 _zAvailable from publisher's website |
| 999 |
_c19332614 _d19332614 |
||